Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders

Summary

The goal of this clinical research study is to learn the highest tolerable dose of phenethyl isothiocyanate (PEITC) that can be given to patients who have a lymphoproliferative disorder that has been treated with fludarabine. The safety of PEITC will also be studied.

Timeline

Start

2013-05

Primary completion

2015-05

Completion

—

Drugs

Indications